Skip to main content
. Author manuscript; available in PMC: 2018 Feb 9.
Published in final edited form as: Gynecol Oncol. 2009 Jun 12;114(3):472–479. doi: 10.1016/j.ygyno.2009.05.012

Table 1.

Association between clinical characteristics and c-MYC amplification or polysomy for chromosome 8.

Total
Cases
c-MYC amplificationa c-MYC amplificationb Polysomy for chromosome 8c



≥ 2 c-MYC/CEP8 copies ≥ 1.5 c-MYC/CEP8 copies ≥ 4 CEP8 copies



No Yes P* No Yes P* No Yes p*
Patient age in years 0.479 0.382 <0.001
  <50 30 20 (66.7) 10 (33.3) 10 (33.3) 20 (66.7) 27 (90.0) 3 (10.0)
  50–59 26 17 (65.4) 9 (34.6) 10 (38.5) 16 (61.5) 19 (73.1) 7 (26.9)
  60–69 28 23 (82.1) 5 (17.9) 15 (53.6) 13 (46.4) 13 (46.4) 15 (53.6)
  ≥ 70 13 9 (69.2) 4 (30.8) 4 (30.8) 9 (69.2) 13 (100.0) 0 (0.0)
Race 0.430 0.489 0.860
  Caucasian 86 59 (68.6) 27 (31.4) 36 (41.9) 50 (58.1) 64 (74.4) 22 (25.6)
  African American 6 5 (83.3) 1 (16.7) 1 (16.7) 5 (83.3) 4 (66.7) 2 (33.3)
  Otherd 5 5 (100.0) 0 (0.0) 2 (40.0) 3 (60.0) 4 (80.0) 1 (20.0)
GOG performance status 1.000 0.321 0.775
  Asymptomaticscore 0/1 77 55 (71.4) 22 (28.6) 33 (42.9) 44 (57.1) 58 (75.3) 19 (24.7)
  Symptomaticscore 2 20 14 (70.0) 6 (30.0) 6 (30.0) 14 (70.0) 14 (70.0) 6 (30.0)
Tumor stage 0.646 0.287 0.633
  Stage III 60 44 (73.3) 16 (26.7) 27 (45.0) 33 (55.0) 43 (71.7) 17 (28.3)
  Stage IV 37 25 (67.6) 12 (32.4) 12 (32.4) 25 (67.6) 29 (78.4) 8 (21.6)
Histologic cell type 0.179 0.051 0.234
  Serous 72 53 (73.6) 19 (26.4) 29 (40.3) 43 (59.7) 51 (70.8) 21 (29.2)
  Endometrioid 9 8 (88.9) 1 (11.1) 7 (77.8) 2 (22.2) 9 (100.0) 0 (0.0)
  Clear cell 2 1 (50.0) 1 (50.0) 0 (0.0) 2 (100.0) 2 (100.0) 0 (0.0)
  Mucinous 3 1 (33.3) 2 (66.7) 1 (33.3) 2 (66.7) 3 (100.0) 0 (0.0)
  Other cell types 11 6 (54.5) 5 (45.5) 2 (18.2) 9 (81.8) 7 (63.6) 4 (36.4)
Tumor grade 0.453 0.386 0.652
  1well differentiated 6 3 (50.0) 3 (50.0) 2 (33.3) 4 (66.7) 5 (83.3) 1 (16.7)
  2moderately differentiated 44 31 (70.5) 13 (29.5) 21 (47.7) 23 (52.3) 34 (77.3) 10 (22.7)
  3poorly differentiated/not graded 47 35 (74.5) 12 (25.5) 16 (34.0) 31 (66.0) 33 (70.2) 14 (29.8)
Measurable disease 1.000 0.837 0.019
  Non-measurable 44 31 (70.5) 13 (29.5) 17 (38.6) 27 (61.4) 38 (86.4) 6 (13.6)
  Measurable 53 38 (71.7) 15 (28.3) 22 (41.5) 31 (58.5) 34 (64.2) 19 (35.8)
Treatment 1.000 1.000 1.000
  Cyclophos + cisplatin 52 37 (71.2) 15 (28.8) 21 (40.4) 31 (59.6) 39 (75.0) 13 (25.0)
  Paclitaxel + cisplatin 45 32 (71.1) 13 (28.9) 18 (40.0) 27 (60.0) 33 (73.3) 12 (26.7)
Total 97 69 (71.1) 28 (28.9) 39 (40.2) 58 (59.8) 72 (74.2) 25 (25.8)
a

c-MYC amplification was categorized as ‘No' when tumors had <2 copies of c-MYC/CEP8 per cell or ‘Yes' when tumors had ≥ 2 copies of c-MYC/CEP8 per cell. Results presented as cases with row percentages in parentheses.

b

c-MYC amplification was categorized as ‘No' when tumors had < 1.5 copies of c-MYC/CEP8 per cell or ‘Yes’ when tumors had ≥ 1.5 copies of c-MYC/CEP8 per cell. Results presented as cases with row percentages in parentheses.

c

Polysomy for chromosome 8 was categorized as ‘No' when tumors had < 4 copies of CEP8 per cell or ‘Yes' when tumors had ≥ 4 copies of CEP8 per cell. Results presented as cases with row percentages in parentheses.

d

Other includes two Asians, one American Indian, and two with an unspecified race.

*

p-value based on Fisher's Exact Test.